Citation: Fr. Hirsch et Hh. Hansen, SHOULD MAINTENANCE CHEMOTHERAPY BE USED TO TREAT SMALL-CELL LUNG-CANCER - ARBITER, European journal of cancer, 34(8), 1998, pp. 1154-1155
Authors:
HANDBERG J
WESSEL V
LARSEN L
HERRSTEDT J
HANSEN HH
Citation: J. Handberg et al., RANDOMIZED, DOUBLE-BLIND COMPARISON OF GRANISETRON VERSUS GRANISETRONPLUS PREDNISOLONE AS ANTIEMETIC PROPHYLAXIS DURING MULTIPLE-DAY CISPLATIN-BASED CHEMOTHERAPY, Supportive care in cancer, 6(1), 1998, pp. 63-67
Citation: Hh. Hansen et Jd. Mikkelsen, LONG-TERM EFFECTS ON SEROTONIN TRANSPORTER MESSENGER-RNA EXPRESSION OF CHRONIC NEONATAL EXPOSURE TO A SEROTONIN REUPTAKE INHIBITOR, European journal of pharmacology, 352(2-3), 1998, pp. 307-315
Authors:
HANSEN HS
LAURITZEN L
MOESGAARD B
STRAND AM
HANSEN HH
Citation: Hs. Hansen et al., FORMATION OF N-ACYL-PHOSPHATIDYLETHANOLAMINES AND N-ACYLETHANOLAMINES- PROPOSED ROLE IN NEUROTOXICITY, Biochemical pharmacology, 55(6), 1998, pp. 719-725
Authors:
NIELSEN SE
ZEUTHEN J
PERSSON B
SVEDBERG A
PERSSON R
WEINER LM
HANSEN HH
Citation: Se. Nielsen et al., A PHASE-I TRIAL OF ESCALATING REPEATED DOSES OF PNU-214565 IN PATIENTS WITH ADVANCED COLORECTAL AND OTHER GASTROINTESTINAL ADENOCARCINOMAS, European journal of cancer, 33, 1997, pp. 383-383
Authors:
PAPPOT H
HOYERHANSEN G
RONNE E
HANSEN HH
BRUNNER N
DANO K
GRONDAHLHANSEN J
Citation: H. Pappot et al., ELEVATED PLASMA-LEVELS OF UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR INNONSMALL CELL LUNG-CANCER PATIENTS, European journal of cancer, 33(6), 1997, pp. 867-872
Authors:
BLAABJERG F
FREYSSON S
HANSEN HH
HANSEN S
Citation: F. Blaabjerg et al., A NEW OPTIMIZED SPACE-VECTOR MODULATION STRATEGY FOR A COMPONENT-MINIMIZED VOLTAGE-SOURCE INVERTER, IEEE transactions on power electronics, 12(4), 1997, pp. 704-714
Authors:
KRARUPHANSEN A
PEDERSEN H
ANDERSEN E
ANDERSEN H
HANSEN HH
Citation: A. Kraruphansen et al., EARLY CLINICAL INVESTIGATION OF SULOFENUR WITH A DAILY SCHEDULE IN ADVANCED SOLID TUMORS, Investigational new drugs, 15(2), 1997, pp. 147-151
Citation: Hh. Hansen et Jb. Sorensen, EFFICACY OF SINGLE-AGENT GEMCITABINE IN ADVANCED NONSMALL CELL LUNG-CANCER - A REVIEW, Seminars in oncology, 24(2), 1997, pp. 38-41
Citation: G. Strauss et al., PHASE-II TRIAL OF HIGH-DOSE CISPLATIN PLUS IFOSFAMIDE AS FIRST-LINE FOLLOWED BY CARBOPLATIN AS SECOND-LINE TREATMENT IN EPITHELIAL OVARIAN-CARCINOMA, Gynecologic oncology, 66(1), 1997, pp. 66-70
Citation: Hh. Hansen et al., NEONATAL ADMINISTRATION OF THE SELECTIVE SEROTONIN REUPTAKE INHIBITORLU 10-134-C INCREASES FORCED SWIMMING-INDUCED IMMOBILITY IN ADULT RATS - A PUTATIVE ANIMAL-MODEL OF DEPRESSION, The Journal of pharmacology and experimental therapeutics, 283(3), 1997, pp. 1333-1341
Authors:
STRAUSS G
LUND B
HANSEN M
HANSEN OP
HANSEN HH
Citation: G. Strauss et al., COMBINED HIGH-DOSE PLATINUM AND ETOPOSIDE IN PREVIOUSLY UNTREATED OVARIAN-CANCER PATIENTS WITH RESIDUAL DISEASE, International journal of gynecological cancer, 6(5), 1996, pp. 410-414
Authors:
KRISTENSEN CA
JENSEN PB
POULSEN HS
HANSEN HH
Citation: Ca. Kristensen et al., SMALL-CELL LUNG-CANCER - BIOLOGICAL AND THERAPEUTIC ASPECTS, Critical reviews in oncology/hematology, 22(1), 1996, pp. 27-60
Authors:
LASSEN U
KRISTJANSEN PEG
OSTERLIND K
BERGMAN B
SIGSGAARD TC
HIRSCH FR
HANSEN M
DOMBERNOWSKY P
HANSEN HH
Citation: U. Lassen et al., SUPERIORITY OF CISPLATIN OR CARBOPLATIN IN COMBINATION WITH TENIPOSIDE AND VINCRISTINE IN THE INDUCTION CHEMOTHERAPY OF SMALL-CELL LUNG-CANCER - A RANDOMIZED TRIAL WITH 5 YEARS FOLLOW-UP, Annals of oncology, 7(4), 1996, pp. 365-371
Authors:
HARTLEYASP B
HANSSON K
VIBEPETERSEN J
HANSEN HH
POLACEK J
ELLMAN M
GUNNARSSON PO
Citation: B. Hartleyasp et al., CHROMOSOME-ABERRATIONS AND PHARMACOKINETICS IN PATIENTS RECEIVING TAUROMUSTINE AS EITHER A SINGLE OR A REPEATED DOSE, Cancer chemotherapy and pharmacology, 38(4), 1996, pp. 309-316
Authors:
ARDIZZONI A
HANSEN HH
DOMBERNOWSKY P
KAPLAN S
POSTMUS PE
GAMUCCI T
SCHAEFER B
WANDERS J
VERWEIJ J
Citation: A. Ardizzoni et al., PHASE-II STUDY OF TOPOTECAN IN REFRACTORY AND SENSITIVE SMALL-CELL LUNG-CANCER (SCLC), European journal of cancer, 31A, 1995, pp. 84-84
Citation: Hh. Hansen, HAVE THE NEW AGENTS DEVELOPED IN THE EARLY 1990S CHANGED THE TREATMENT OF LUNG-CANCER, European journal of cancer, 31A, 1995, pp. 609-609
Citation: Jb. Sorensen et al., COMBINATION CHEMOTHERAPY INCLUDING IFOSFAMIDE, CARBOPLATIN, AND CISPLATIN IN ADVANCED NON-SMALL-CELL LUNG-CANCER (NSCLC), European journal of cancer, 31A, 1995, pp. 1108-1108
Citation: Jb. Sorensen et al., SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC-HORMONE (SIADH) IN MALIGNANT DISEASE, Journal of internal medicine, 238(2), 1995, pp. 97-110